Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
๋์ ์ฑ์ฅ
ํ์ฌ์ ๋งค์ถ์ ์ง๋ 3๋
๊ฐ ๊พธ์คํ ์ฑ์ฅํด์์ผ๋ฉฐ, ์ฐํ๊ท 172.37%์ ์ฆ๊ฐ์จ์ ๊ธฐ๋กํ์ต๋๋ค.
์ฑ์ฅ ์ค
ํ์ฌ๋ ์ฑ์ฅ ๋จ๊ณ์ ์์ผ๋ฉฐ, ์ต์ ์ฐ๊ฐ ์์ต์ ๋ฏธํ 301.65K์ ๋ฌํฉ๋๋ค.
๊ณ ์์ต ์ฑ์ฅ
ํ์ฌ์ ์์ด์ต์ ์
๊ณ ์ ๋๋ฅผ ๋ฌ๋ฆฌ๊ณ ์์ผ๋ฉฐ, ์ต๊ทผ ์ฐ๊ฐ ์์ด์ต์ ๋ฏธํ 301.65K์ ๋ฌํฉ๋๋ค.
๊ณผ๋ ํ๊ฐ๋
ํ์ฌ์ ์ต์ PE์ -0.74๋ก, ์ต๊ทผ 3๋
๊ธฐ์ค ๋์ ๋ฐฑ๋ถ์ ๋ฒ์์ ์ํฉ๋๋ค.
๊ธฐ๊ด ๋งค์
์ต์ ๊ธฐ๊ด ๋ณด์ ์ฃผ์ ์๋ 1.43M์ฃผ์ด๋ฉฐ, ์ ๋ถ๊ธฐ ๋๋น 26.88% ์ฆ๊ฐํ์ต๋๋ค.
์ ์์ค ์ฌ์ด๋จผ์ค๊ฐ ๋ณด์
์คํ ํฌ์์ ์ ์์ค ์ฌ์ด๋จผ์ค์ด(๊ฐ) ์ด ์ฃผ์ 6.65K์ฃผ๋ฅผ ๋ณด์ ํ๊ณ ์์ต๋๋ค.
์์ฅ ํ๋ ๊ฐ์
ํ์ฌ๋ ํฌ์์๋ค์ ๊ด์ฌ์ด ์ค์ด๋ค์ด, ์ต๊ทผ 20์ผ๊ฐ ํ์ ์จ์ด -0.75์
๋๋ค.